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Abstract The primary objective of this study was to investi-
gate whether the presence of comorbidities was associated with
a lower health-related quality of life (HRQOL) in elderly pa-
tients with chronic myeloid leukemia (CML). A sample of 174
CML patients aged 60 years or above was analyzed. HRQOL
was assessed with the Medical Outcomes Study 36-Item Short-
Form Health Survey (SF-36). A number of pre-selected
sociodemographic and disease-related factors were considered
as potential confounding factors for the association between
comorbidity and HRQOL. Mean age of the 174 patients ana-
lyzed was 70 years (range 60–87 years) and 55 % were male.
Overall, 111 patients (64 %) reported at least one comorbidity.
Analysis stratified by age group category showed a greater
proportion of patients with comorbidities in the older sub-
group population (≥70 years) compared to younger patients
(60 to 69 years). Differences in HRQOL outcomes between
patients with no comorbidity at all and those with two or more
comorbid conditions were at least twice the magnitude of a
clinically meaningful difference in all the physical and mental
health scales of the SF-36. In multivariate analysis, after
adjusting for key confounding factors, the following scales
were significantly lower in those with comorbidity: general
health (p<0.001), bodily pain (p<0.001), physical functioning
(p=0.002), and vitality (p=0.002). Assessing comorbidity in
elderly patients with CML is important to facilitate identifica-
tion of those most in need of HRQOL improvements.
Keywords Comorbidity . Quality of life . Chronic myeloid
leukemia
Introduction
The introduction of tyrosine kinase inhibitors (TKIs) in the
treatment for chronic myeloid leukemia (CML) has greatly
changed the prognosis of patients. With the advent of first
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TKI, namely imatinib, also elderly patients, usually candidate
to palliative approach, have been treated and cured [1]. A 5-
year relative survival of elderly CML patients (≥65 years) was
shown to be comparable to that of younger patients [2]. As
recent data from large population-based registries report a me-
dian age at diagnosis of 56 years [3], it is reasonable to con-
sider that many of the CML patients currently under treatment
have even a greater median age. Nonetheless, elderly patients
and those with comorbidity have not been adequately repre-
sented in several of the pivotal clinical efficacy trials conduct-
ed so far [4–6].
While in general, elderly people are more likely to report
comorbid medical conditions, recent data also shows that pa-
tients with a cancer diagnosis report significantly more comor-
bid conditions than do their peers without a cancer diagnosis
[7]. According to Feinstein’s definition [8], comorbidity is any
distinct additional clinical entity pre-existent or occurring dur-
ing the course of a primary disease.
The possibility to prescribe other two TKIs (i.e., nilotinib
and dasatinib) as first-line treatment, in addition to imatinib,
makes the selection of the most appropriate treatment for in-
dividual patients a challenge. Therefore, considering individ-
ual characteristics, including comorbidity, is critical [6, 9].
In the coming decades, the prevalence of elderly patients
livingwith CMLwill substantially increase given the dramatic
improvements in treatment outcomes for this disease [10, 11].
Understanding the relationships between comorbidity, treat-
ment outcomes, and patient’s health-related quality of life
(HRQOL) is thus essential to robustly inform clinical deci-
sion-making.
There is convincing evidence showing that elderly patients
treated with imatinib are able to achieve similar rates of cyto-
genetic and molecular responses compared to younger pa-
tients, although with increased incidence of temporary discon-
tinuation or dose reduction due to toxicity [12, 13]. While
some data exists on the relationships between comorbidity
and clinical outcomes in CML, to our knowledge, the impact
of comorbidity on patient-reported HRQOL in elderly CML
patients has not been investigated. Considering the lifelong
nature of current TKI therapies, even low-grade side effects
can significantly impair patients’ daily functioning and well-
being [14]. Therefore, improving HRQOL has become an
important goal of modern CML therapies [15]. We have pre-
viously shown that CML patients aged 60 years or older, who
respond to imatinib therapy (i.e., at least in complete cytoge-
netic response), can expect to have a HRQOL profile similar
to that of their peers in the general population [16].
The primary objective of this analysis was to investigate
whether the presence and number of comorbidities is associated
with lower physical and mental HRQOL aspects in this elderly
(i.e., aged 60 or older) CML population. Secondary objectives
were to assess prevalence of comorbidities and to evaluate
whether these were associated with greater symptom severity.
Patients and methods
Study population
Patients were previously enrolled in a large multicentre CML
survivorship (n=422) study investigating long-term effects of
first-line imatinib therapy. Patients’HRQOL results, inclusion
criteria, and study logistic have been previously reported [16].
Briefly, patients had to be on treatment for at least 3 years and
at least in complete cytogenetic response (CCyR) at the time
of study entry. Patients could be enrolled regardless of number
and type of comorbidity. Patients with a secondary malignan-
cy and having psychiatric conditions or major cognitive dys-
functions hampering a self-reported evaluation, at study entry,
were excluded. The current analysis is based on patients aged
60 or older (n=174) enrolled in this study [16].
Ethic committees of participating centers approved the
study and all patients provided written informed consent.
Health-related quality of life and symptom severity
The Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36) was used to assess HRQOL. It consists of
36 items yielding eight scales: physical functioning, role lim-
itations due to physical problems, bodily pain, general health
perceptions, vitality, social functioning, role limitations due to
emotional problems and mental health. Each scale provides a
score ranging between 0 and 100 with higher scores indicating
better outcomes [17].
Patient-reported symptomswere evaluated with a previously
developed checklist for assessing the severity a core set of
symptoms for CML patients [18]. The following symptoms
were evaluated: abdominal discomfort, diarrhea, edema, fa-
tigue, headache, muscular cramps, musculoskeletal pain, nau-
sea, and skin problems. Each symptomwas scored as: not at all,
a little, quite a bit, and very much. To ease outcome interpreta-
tion in this report, and similarly to other symptom ratings in-
cluded in well-validated questionnaires [19], raw scores were
linearly transformed into a standardized scale ranging from 0 to
100 with higher scores indicating greater symptom severity.
Assessment of comorbidity
Patients themselves reported comorbidity at the time of
HRQOL assessment by completing an adapted version of
the Charlson Comorbidity Index [20]. The questionnaire ad-
dressed the following comorbidities: osteoarthritis/rheuma-
tism, vascular pathology, diabetes, pulmonary problems, obe-
sity, liver problems, renal pathology, myocardial infarction,
ulcer, and other conditions. Also, a free text field was added
to allow patients entering any other comorbidity.
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Disease and sociodemographic variables analyzed
Key variables potentially contributing to explaining patient’s
HRQOL were considered and these were selected based on
clinical relevance for the purpose of this analysis. These were
grouped into (1) disease-related and (2) sociodemographic
factors. Disease-related factors included time since diagnosis,
Sokal risk at diagnosis, and achievement of a complete mo-
lecular response. Sociodemographic factors included age, sex,
education, and social support. This latter was included being a
potential determinant of HRQOL in cancer survivors and be-
ing associated with survival in elderly cancer patients [21, 22].
This was assessed with the well-validated multidimensional
scale of perceived social support (MSPSS) [23] that consists
of 12 items that evaluate perceptions of social support from
three main sources: friends, family members, and significant
others. It also yields a total score (i.e., global social support)
that was used for the purpose of this analysis.
Statistical analysis
Analyses were performed on 174 CML patients aged at least
60 years. As there is paucity of research regarding HRQOL
and comorbidity in elderly CML patients, all SF-36 scales
were investigated in this study as primary scales. Patients were
classified in three groups by number of comorbidities and
categorized as no comorbidity at all, one comorbidity, and
two comorbidities or more. Differences were investigated
among such groups in self-reported symptoms and SF-36
scales by Kruskal-Wallis test (α=0.05). Also, multivariate
analysis of covariance (ANCOVA) was used to assess differ-
ences in SF-36 scales by number of comorbidities, adjusting
for other key variables selected on clinical grounds. Based on
multivariate ANCOVA, the proportion of variance of SF-36
scales explained by presence of comorbidities was investigat-
ed using the total eta-square index. This index provides the
specific contribution of each variable included in the model in
explaining the outcome variance. For descriptive purposes,
proportions of explained variance of variables other than pres-
ence of comorbidities were grouped into “disease-related” and
“sociodemographic” variables. Clinical significance of differ-
ences in HRQOL outcomes was also evaluated in this study,
defined as at least eight points on each SF-36 scale [24]. Sta-
tistical significance for SF-36 scales was Bonferroni corrected
to account for multiple testing. All analyses were performed
with SAS v.4 (SAS Institute, Inc., Cary, NC, USA) and SPSS
v. 20.
Results
Mean age of the 174 patients analyzed was 70 years (range
60–87 years) and 55%were male. Mean time between date of
diagnosis and study participation was 5.5 years (SD 1.9). Sev-
enty percent of patients were receiving a standard dose of
imatinib of 400 mg/day at the time of survey. Sokal risk clas-
sification at diagnosis was low in 37 % of the patients, inter-
mediate in 51 %, and high in 12 %. Overall, 111 patients
(64 %) reported at least one comorbidity. Of the 202 comor-
bidities reported by these patients, these were classified as
follows: osteoarthritis/rheumatism (30 % patients), vascular
pathology (17 %), diabetes (10 %) and pulmonary problems
(9 %), obesity (6 %), liver problems (6 %), renal pathology
(5 %), myocardial infarction (4 %), ulcer (3 %), and other
comorbid conditions (24 %). Sixty-three patients (36 %) did
not report any comorbidity, 55 (32 %) reported only one co-
morbidity, and 56 (32 %) reported two or more comorbidities.
Analysis stratified by age group category showed a greater
proportion of patients with comorbidities in the older sub-
group population (≥70 years) compared to younger patients
(60 to 69 years). For example, within the group of patients
with no comorbidity at all, 62 % were aged between 60 to
69 years while only 38 % were aged 70 years or more. Char-
acteristics of patients stratified by number of comorbidities are
reported in Table 1.
Univariate analysis of comorbidity and health-related
quality of life and symptom burden
Patients with no comorbidity (Com0) had overall statistically
significant better outcomes (i.e., higher scores) across all the
physical and mental health scales of the SF-36 compared to
those with either one comorbidity (Com1) or two or more
comorbid conditions (Com≥2) (Fig. 1).
Differences between groups Com0 and Com≥2 were at least
twice the magnitude of a clinically meaningful difference for all
the eight scales (physical and mental health) of the SF-36 ques-
tionnaire. The differences in bodily pain (Δ=25.3 points) and
role physical (Δ=24.1 points) were at least three times the mag-
nitude of a clinically meaningful difference. For physical func-
tioning (Δ=23), general health (Δ=22.6), and role-emotional
(Δ=22.4), the differences between Com0 and Com≥2 were just
below three times the magnitude of a clinically meaningful
difference.
Exploratory analysis comparing HRQOL profile of our el-
derly population stratified by number of comorbidities with
that of the general population (adjusted by age and gender)
revealed that CML patients with no comorbidity had broadly
even better outcomes than their peers in some domains (data
not shown).
Symptom severity by number of comorbidities is depicted in
Fig. 2. Statistically significant differences were found in symp-
tom mean scores by comorbidity for muscular cramps (p=
0.045), musculoskeletal pain (p=0.003), edema (p=0.008), and
fatigue (p<0.001).
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Table 1 Sociodemographic and clinical characteristics of elderly CML patients by number of comorbidities
Variable No comorbidity (n=63) One comorbidity (n=55) Two or more
comorbidities (n=56)
Total (n=174)
Age, years
Mean (SD) 68.89 (7.00) 71.57 (6.58) 70.70 (5.67) 70.32 (6.52)
Median 67.08 71 69.83 69.38
Range 60.08–86.83 60.67–84.25 60.58–84.50 60.08–86.83
60–69 39 (61.90) 23 (41.82) 29 (51.79) 91 (52.30)
≥70 24 (38.10) 32 (58.18) 27 (48.21) 83 (47.70)
Sex, n (%)
Male 38 (60.32) 34 (61.82) 24 (42.86) 96 (55.17)
Female 25 (39.68) 21 (38.18) 32 (57.14) 78 (44.83)
Education, n (%)
Primary school 39 (62.91) 38 (70.38) 40 (71.43) 117 (68.02)
High school 11 (17.74) 10 (18.51) 13 (23.21) 34 (19.78)
Master’s degree and further 12 (19.35) 6 (11.11) 3 (5.36) 21 (12.20)
Missing 1 1 0 2
Living arrangements, n (%)
Living with someone 48 (76.19) 40 (72.73) 38 (67.86) 126 (72.41)
Living alone 15 (23.81) 15 (27.27) 18 (32.14) 48 (27.59)
Global social support (MSPSS)
Mean (SD) 5.87 (1.32) 5.73 (1.34) 5.27 (1.49) 5.63 (1.40)
Median 6.25 6.17 5.50 6
Range 1.17–7.00 1.08–7.00 1.00–7.00 1.00–7.00
ECOG performance status, n (%)
0 35 (55.55) 36 (65.45) 33 (60.00) 104 (60.11)
1 24 (38.10) 18 (32.73) 21 (38.18) 63 (36.42)
2 4 (6.35) 1 (1.82) 1 (1.82) 6 (3.47)
3 0 0 1 1
Previous history of cancer, n (%)
No 55 (87.3) 49 (90.74) 44 (78.57) 148 (85.55)
Yes 8 (12.7) 5 (9.26) 12 (21.43) 25 (14.45)
Missing 0 1 0 1
Sokal risk at diagnosis, n (%)
Low (<0.8) 22 (35.48) 21 (40.38) 19 (35.18) 62 (36.90)
Intermediate (0.8–1.2) 33 (53.23) 24 (46.15) 28 (51.85) 85 (50.60)
High (>1.2) 7 (11.29) 7 (13.46) 7 (12.96) 21 (12.50)
Missing 1 3 2 6
Time since diagnosis, years
Mean (SD) 5.58 (1.79) 5.39 (2.12) 5.40 (1.83) 5.46 (1.90)
Median 5.33 4.83 5.08 5.08
Range 3.00–12.17 3.00–11.50 3.00–10.75 3.00–12.17
Current prescribed dose of imatinib (mg/day)
300 mg/day 12 (19.05) 12 (21.82) 5 (8.93) 29 (16.67)
400 mg/day 44 (69.84) 39 (70.91) 39 (69.64) 122 (70.11)
600 mg/day 2 (3.17) 3 (5.45) 2 (3.57) 7 (4.02)
Other 5 (7.94) 1 (1.82) 10 (17.86) 16 (9.2)
Complete molecular response, n (%)
No 24 (38.10) 27 (49.09) 19 (33.93) 70 (40.23)
Yes 39 (61.90) 28 (50.91) 37 (66.07) 104 (59.77)
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Multivariate analysis of the association of comorbidity
and health-related quality of life
In a multivariate ANCOVA, we adjusted the comparison of
the three comorbidity groups with regard to the SF-36 do-
mains for important sociodemographic and disease-related pa-
tient characteristics. In this analysis, four out of eight SF-36
scales (physical functioning, bodily pain, general health, and
vitality) remained significantly different among comorbidity
groups even after Bonferroni correction for multiple testing.
Details for this analysis are given in Tables 2 and 3.
To investigate the relative importance of comorbidity in com-
parison with disease-related and sociodemographic factors, we
calculated proportions of explained variance in terms of total eta-
square index (Fig. 3). For each scale, we report proportions of
variance which are uniquely explained by either presence of
Table 1 (continued)
Variable No comorbidity (n=63) One comorbidity (n=55) Two or more
comorbidities (n=56)
Total (n=174)
Adverse events (any grade), n (%)
Yes 22 (34.92) 19 (34.55) 27 (48.21) 68 (39.08)
No 41 (65.08) 36 (65.45) 29 (51.79) 106 (60.92)
SD standard deviation, ECOG Eastern Cooperative Oncology Group, MSPSS multidimensional scale of perceived social support
Fig. 1 a, b Health-related quality of life profile of elderly CML patients
by number of comorbidities. Mean outcomes for the eight scales of the
SF-36 questionnaire by number of patients’ self-reported current
comorbidities are shown. For each scale, higher scores denote better
outcomes and lower scores worse outcomes. p value refers to the
overall comparison of mean scores among patients with no, one, or at
least two comorbidities, under the null hypothesis of no difference. Δ
represents the positive score difference between patients with no
comorbidities at all and those with either one or at least two
comorbidities. Values reported in the figure were rounded. A single
asterisk denotes that the score difference exceeds the minimally
important difference (i.e., 8 points). Double asterisks indicate that the
score difference equals to or exceeds twice the minimally important
difference. Triple asterisks entail that the score difference equals to or
exceeds three times the minimally important difference
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comorbidities, disease-related, or sociodemographic variables.
We found that for general health (15 % explained variance)
and bodily pain (12 % explained variance), the presence of co-
morbidities explained substantially more variance than disease-
related or sociodemographic variables.
Discussion
We have found that some two thirds of CML patients aged
60 years or above reported at least one comorbidity and that
the presence of this was associated with important impair-
ments in both physical and mental health domains. This neg-
ative association with HRQOL outcomes was particularly re-
markable in patients who reported two or more comorbid
conditions.
In a recent large population-based registry study, it was found
that 55 % of the 2904 CML patients analyzed had at least one
comorbidity. Although this percentage is slightly lower than that
found in our study (i.e., 64 %), it should be noted that in this
registry, also patients younger than 60 years were represented.
Saussele and colleagues [25] recently showed that comorbid-
ity at diagnosis was an independent prognostic factor for shorter
survival in imatinib-treated CML patients regardless of age.
They concluded that the presence of comorbidity is more impor-
tant than the disease itself in determining the survival of patients.
Our findings complement this remarkable data [25] by showing
that comorbidity also heavily influence HRQOL of elderly pa-
tients. Notably, in our analysis of variance, the presence of co-
morbidities was by far the most important contributor in deter-
mining the subjective general health status scale of the SF-36.
Considering the paucity of research on this topic, it is dif-
ficult to compare our findings with other similar CML studies.
However, our results are broadly consistent with the few stud-
ies conducted in patients with other hematologic malignancies
(mainly Hodgkin’s and non-Hodgkin’s lymphoma patients)
indicating the negative impact of comorbidities on patients’
HRQOL [26–28].
In our previous study [29] analyzing the whole sample, we
found that fatigue was independently associated with all
HRQOL physical and mental health domains of the SF-36.
In this analysis, specifically investigating the role of comor-
bidity on HRQOL in the elderly sub-population (i.e., with a
substantial higher number of comorbid conditions), we found
that comorbidity was associated with both HRQOL and fa-
tigue. Taken together, both findings might suggest that, in
elderly patients, comorbidity could possibly impair HRQOL
by raising patients’ fatigue levels. Whether the presence of
comorbidities can determine an increased symptom severity,
which can in turn negatively affect more general aspects of
HRQOL, should be investigated in future prospective studies.
The identification of a causal model on the pathways of how
comorbidity could influence the various aspects of HRQOL,
would be important to inform the development of future inter-
vention studies in elderly patients.
Our findings have two important implications. From a clin-
ical practice perspective, our results suggest that elderly pa-
tients with comorbidities should be more closely monitored
due to their poorer HRQOL outcomes. They might represent a
specific population who can benefit the most from supportive
care programs. Another implication is for better designing and
interpreting future HRQOL research studies of elderly CML
patients. Our results indicate that comorbidity should be con-
sidered as a key variable to adjust for, in order to increase
robustness of study results and outcome interpretation. There-
fore, routinely collecting and quantifying comorbid conditions
possibly using well-validated indices in clinical practice and
research is strongly recommended.
Our study has limitations. First, given the cross-sectional
design, we cannot draw conclusions on causal relationships
Fig. 2 Self-reported symptom severity of elderly CML patients by
number of comorbidities. For each symptom, higher scores denote
higher symptom severity while lower scores indicate lower symptom
severity. Values reported in the figure were rounded. p value refers to
the overall comparison of mean scores among patients with no, one, or
at least two comorbidities, under the null hypothesis of no difference
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between comorbidity and HRQOL or specific symptoms. Al-
so, given the self-reported nature of comorbidity data collec-
tion, we cannot rule out the possibility of underreporting of
comorbid conditions. For example, as major cognitive dys-
function or psychiatric problems were an exclusion criterion
of the original study, this might have contributed to the
underreporting of psychological-related comorbidities.
These limitations notwithstanding, our study also has
strengths. Our sample was homogenous with regard to therapy
received, thus ruling out the potential confounding effect of
type and schedule of therapy when analyzing the association
between comorbidity and HRQOL. Also, we accounted for the
role of social support, which might be particularly important in
determining HRQOL of elderly people. Finally, our results
have been generated in an observational setting thusmost likely
to be generalizable to CML patients seen in daily practice.
In conclusion, the presence of comorbidity in elderly CML
patients is associated with diminished physical and mental
health well-being. Therefore, assessing comorbidity in elderly
patients is important to facilitate identification of those most in
need of HRQOL improvements. It is likely that assessing
comorbidities is also equally important in younger patients
and this should be examined in future studies.
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Fig. 3 Explained variance (%) of health-related quality of life of elderly
CML patients. Mean outcomes for the eight scales of the SF-36
questionnaire are shown. For each scale, the figure shows the percentage
of variance (total eta-squared) explained in the multivariate ANCOVA
model (as reported in Tables 2 and 3), by presence of comorbidities,
sociodemographic factors (age, sex, education, and social support), and
disease-related variables (Sokal risk, complete molecular response, time
since diagnosis). Values reported in the figure were rounded. A single
asterisk signifies that the explained variance is less than 1 %
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